Zhejiang Hisun Pharmaceutical Hits Day High with Strong 4.01% Intraday Surge

Zhejiang Hisun Pharmaceutical Co., Ltd. has experienced a notable increase of 4.01% on March 6, 2026, reaching an intraday high of CNY 10.39. This performance stands out against the backdrop of the China Shanghai Composite, which saw a modest gain of 0.38% on the same day. In terms of performance metrics, Zhejiang Hisun has shown a year-to-date increase of 4.85%, outperforming the broader market index, which is up 3.91%. Over the past year, the stock has delivered a return of 21.71%, closely aligning with the Shanghai Composite's 21.98% gain. However, the stock has faced challenges over longer periods, with a three-year decline of 5.98% and a five-year drop of 36.92%. The company maintains a market capitalization of CNY 11,262 million and exhibits a price-to-earnings ratio of 25.00. With a return on equity of 6.78% and a price-to-book ratio of 1.32, Zhejiang Hisun Pharmaceutical continues to navigate the competitive pharmaceuticals and biotechnology landscape. The stock also offers a dividend yield of 2.25%, reflecting its commitment to returning value to shareholders.